Personal Home Page

http://medicine.uchicago.edu/faculty_profile/faculty_profile.asp?empl_id=6135

Articles in Scholarly Journals [Incomplete List]

1. The Werner’s syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds
   Cancer Chemotherapy and Pharmacology, 2008
2. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours
   European Journal of Cancer, vol. 44, no. 12, pp. 1684–1692, 2008
3. Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Polymorphisms: Are We There Yet?
   Pharmacotherapy, vol. 28, no. 6, pp. 755–768, 2008
4. Role of UGT1A1*6 in irinogenetics in Asians
   Personalized Medicine, vol. 4, no. 4, pp. 431–434, 2007
5. Relationship of EGFR Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines
   Clinical Cancer Research, vol. 13, no. 22, pp. 6788–6795, 2007
6. The Role of SN-38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity
   The Journal of Clinical Pharmacology, vol. 47, no. 1, pp. 78–86, 2007
7. Insights, Challenges, and Future Directions in Irinogenetics
   Therapeutic Drug Monitoring, vol. 29, no. 3, pp. 265–270, 2007
8. Lack of Association between Common Polymorphisms in UGT1A9 and Gene Expression and Activity
   Drug Metabolism and Disposition, vol. 35, no. 12, pp. 2149–2153, 2007
9. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer
   Cancer Chemotherapy and Pharmacology, vol. 60, no. 6, pp. 811–819, 2007
10. MTHFR and ALL risk: A challenge
    Leukemia and Lymphoma, vol. 47, no. 7, pp. 1203–1204, 2006
11. The role of pharmacogenetics in cancer therapeutics
    British Journal of Clinical Pharmacology, vol. 62, no. 1, pp. 35–46, 2006
12. Effects of Green Tea Compounds on Irinotecan Metabolism
    Drug Metabolism and Disposition, vol. 35, no. 2, pp. 228–233, 2006
13. Irinogenetics: What Is the Right Star?
    Journal of Clinical Oncology, vol. 24, no. 15, pp. 2221–2224, 2006
14. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping
    Pharmacogenomics, vol. 7, no. 8, pp. 1211–1221, 2006
15. Effects of Ketoconazole on Glucuronidation by UDP-Glucuronosyltransferase Enzymes
    Clinical Cancer Research, vol. 11, no. 18, pp. 6699–6704, 2005
16. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes
    Pharmacogenetics and Genomics, vol. 15, no. 5, pp. 295–301, 2005
17. 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice
    Toxicology and Applied Pharmacology, vol. 203, no. 2, pp. 106–113, 2005
18. ?Irinogenetics? and UGT1A: from genotypes to haplotypes*1
    Clinical Pharmacology & Therapeutics, vol. 75, no. 6, pp. 495–500, 2004
19. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital
    Clinical Pharmacology & Therapeutics, vol. 76, no. 5, pp. 490–502, 2004
20. A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer
    Cancer Chemotherapy and Pharmacology, vol. 54, no. 5, pp. 377–384, 2004
21. Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan
    Journal of Clinical Oncology, vol. 22, no. 8, pp. 1382–1388, 2004
22. UGT pharmacogenomics
    Pharmacogenetics, vol. 13, no. 8, pp. 517–523, 2003
23. Pharmacogenetics in Cancer Treatment
    Annual Review of Medicine, vol. 54, no. 1, pp. 437–452, 2003
24. A pharmacogenetic study of uridine diphosphate–glucuronosyltransferase 2B7 in patients receiving morphine
    Clinical Pharmacology & Therapeutics, vol. 73, no. 6, pp. 566–574, 2003
25. Pharmacogenomics: road to anticancer therapeutics nirvana?
    Oncogene, vol. 22, no. 42, Article ID 1206958, 7 pages, 2003
26. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients
    British Journal of Clinical Pharmacology, vol. 53, no. 5, pp. 508–518, 2002
27. Effect of methylenetetrahydrofolate reductase 677C?T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients
    International Journal of Cancer, vol. 103, no. 3, pp. 294–299, 2002
28. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report
    European Journal of Clinical Pharmacology, vol. 58, no. 9, pp. 593–595, 2002
29. Pharmacogenetics, vol. 12, no. 9, pp. 725–733, 2002
30. Therapeutic Drug Monitoring, vol. 22, no. 4, pp. 375–382, 2000
31. Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens
    Cancer Chemotherapy and Pharmacology, vol. 43, no. 2, pp. 133–140, 1999
32. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo
    Cancer Chemotherapy and Pharmacology, vol. 43, no. 3, pp. 205–212, 1999
33. Therapeutic Drug Monitoring, vol. 21, no. 3, p. 367, 1999
34. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate
    Cancer Chemotherapy and Pharmacology, vol. 37, no. 5, pp. 409–414, 1996